AGEN
Price
$2.83
Change
-$0.02 (-0.70%)
Updated
Apr 24, 12:27 PM (EDT)
Capitalization
72.64M
NCNA
Price
$0.89
Change
+$0.11 (+14.10%)
Updated
Apr 23 closing price
Capitalization
4.73M
Ad is loading...

AGEN vs NCNA

Header iconAGEN vs NCNA Comparison
Open Charts AGEN vs NCNABanner chart's image
Agenus
Price$2.83
Change-$0.02 (-0.70%)
Volume$300
Capitalization72.64M
NuCana
Price$0.89
Change+$0.11 (+14.10%)
Volume$29.84K
Capitalization4.73M
AGEN vs NCNA Comparison Chart
Loading...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGEN vs. NCNA commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGEN is a Buy and NCNA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (AGEN: $2.85 vs. NCNA: $0.89)
Brand notoriety: AGEN and NCNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGEN: 275% vs. NCNA: 36%
Market capitalization -- AGEN: $72.64M vs. NCNA: $4.73M
AGEN [@Biotechnology] is valued at $72.64M. NCNA’s [@Biotechnology] market capitalization is $4.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGEN’s FA Score shows that 0 FA rating(s) are green whileNCNA’s FA Score has 1 green FA rating(s).

  • AGEN’s FA Score: 0 green, 5 red.
  • NCNA’s FA Score: 1 green, 4 red.
According to our system of comparison, both AGEN and NCNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGEN’s TA Score shows that 4 TA indicator(s) are bullish while NCNA’s TA Score has 4 bullish TA indicator(s).

  • AGEN’s TA Score: 4 bullish, 5 bearish.
  • NCNA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both AGEN and NCNA are a bad buy in the short-term.

Price Growth

AGEN (@Biotechnology) experienced а +72.73% price change this week, while NCNA (@Biotechnology) price change was -1.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.82%. For the same industry, the average monthly price growth was -6.25%, and the average quarterly price growth was -12.37%.

Reported Earning Dates

AGEN is expected to report earnings on Mar 17, 2025.

NCNA is expected to report earnings on Mar 20, 2025.

Industries' Descriptions

@Biotechnology (+6.82% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AGEN($72.6M) has a higher market cap than NCNA($4.73M). AGEN YTD gains are higher at: 4.015 vs. NCNA (-25.210). NCNA has higher annual earnings (EBITDA): -29.33M vs. AGEN (-77.64M). AGEN has more cash in the bank: 44.8M vs. NCNA (11.4M). NCNA has less debt than AGEN: NCNA (221K) vs AGEN (78.4M). AGEN has higher revenues than NCNA: AGEN (160M) vs NCNA (0).
AGENNCNAAGEN / NCNA
Capitalization72.6M4.73M1,537%
EBITDA-77.64M-29.33M265%
Gain YTD4.015-25.210-16%
P/E Ratio0.46N/A-
Revenue160M0-
Total Cash44.8M11.4M393%
Total Debt78.4M221K35,475%
FUNDAMENTALS RATINGS
AGEN vs NCNA: Fundamental Ratings
AGEN
NCNA
OUTLOOK RATING
1..100
2931
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
15
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
4089
P/E GROWTH RATING
1..100
94100
SEASONALITY SCORE
1..100
65n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NCNA's Valuation (15) in the Biotechnology industry is significantly better than the same rating for AGEN (97). This means that NCNA’s stock grew significantly faster than AGEN’s over the last 12 months.

NCNA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AGEN (100). This means that NCNA’s stock grew similarly to AGEN’s over the last 12 months.

NCNA's SMR Rating (97) in the Biotechnology industry is in the same range as AGEN (100). This means that NCNA’s stock grew similarly to AGEN’s over the last 12 months.

AGEN's Price Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for NCNA (89). This means that AGEN’s stock grew somewhat faster than NCNA’s over the last 12 months.

AGEN's P/E Growth Rating (94) in the Biotechnology industry is in the same range as NCNA (100). This means that AGEN’s stock grew similarly to NCNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGENNCNA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 9 days ago
79%
Declines
ODDS (%)
Bearish Trend 9 days ago
89%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
AGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NCNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
INCR1.460.08
+5.80%
Intercure Ltd
KTTA1.620.08
+5.23%
Pasithea Therapeutics Corp
ARLP27.220.24
+0.91%
Alliance Resource Partners LP
NPKI5.74-0.01
-0.17%
NPK International Inc
GMAB20.13-0.14
-0.69%
Genmab A/S ADS